Biotech Values

[biomaven0]

what’s even tougher these days is getting third-party payers to pay a high price for a branded drug that isn’t statsig superior to a drug that’s generic by the time the new branded drug hits the market.

Good point. What that implies is that there will be no new drug development in the vast majority of (non-oncology) drug classes we have today.

Bystolic, Forest's beta-blocker, is an interesting example of a drug that is "somewhat better" than the many other drugs in its class. Basically a better side-effect profile on a number of fronts. Forest has achieved sales of around $400m despite the drug not being on formulary with some major insurers.

Peter